Today's Rundown Featured Story | | | Friday, December 7, 2018 Moderna’s IPO always looked like a record breaker for biotech and came in even larger than expected at $604 million, valuing the company at an eye-watering $7.9 billion. |
|
|
Top Stories Friday, December 7, 2018 AstraZeneca’s tremelimumab has come up short in another phase 3 trial. Having failed to improve outcomes in metastatic non-small cell lung cancer, the anti-CTLA4 antibody has now missed the primary endpoint in a phase 3 advanced head and neck cancer trial. Friday, December 7, 2018 DiaMedica Therapeutics has wrapped up its IPO. The offering gives DiaMedica the cash to take its lead candidate through phase 2 trials in acute ischemic stroke and chronic kidney disease. Friday, December 7, 2018 Six years after Eisai and University College London teamed up to discover new treatments for neurological diseases, they are moving their first candidate into the clinic: a tau-targeting monoclonal antibody for Alzheimer’s disease. Friday, December 7, 2018 The ability to regenerate insulin-producing cells in the pancreas would do the job, but that has so far proven to be an elusive target. A team of Stanford University scientists is now searching for a solution in a common nutrient: zinc. Wednesday, December 5, 2018 Neurimmune is best known for its Alzheimer's partnership with Biogen to develop aducanumab. Now its scientists have used the same technology to design a recombinant human monoclonal antibody that shows potential as treatment for amyotrophic lateral sclerosis (ALS) patients with the misfolded SOD1 protein. Thursday, December 6, 2018 In this week's EuroBiotech Report, UCB commits to U.K., and Lundbeck, Genfit and AstraZeneca post midphase data. Friday, December 7, 2018 The Takeda-Shire megamerger won go-aheads from shareholders; Sun Pharma plummets on reports of a potential government probe and governance issues; J&J and Legend update results from an early-stage myeloma trial testing their much-hyped CAR-T therapy; and more. Friday, December 7, 2018 Xenotransplantation firm eGenesis hired Wes Westlin as its R&D head; Relay added executives to its chemistry and R&D teams for its transition to development stage; and Navidea bought aboard a new CMO focused on imaging biomarkers. Those moves plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
